Ovarian Cancer

Latest News

Ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
Primary Debulking Surgery Maintains Survival Advantage Amid Rising Popularity of NACT With Interval Debulking Surgery

September 17th 2025

Increased use of neoadjuvant chemotherapy (NACT) with interval debulking surgery has changed surgical practice patterns, improving complete resection rates and reducing postoperative complications.

World map | Image Credit: pyty - stock.adobe.com
Ovarian, Uterine Cancers Linked to High BMI Continue to Rise Among Women of Reproductive Age Worldwide

September 14th 2025

BRCA | Image Credit: syahrir - stock.adobe.com
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing

September 4th 2025

Ovarian Cancer Awareness Month | Image Credit: Rana - stock.adobe.com
Ovarian Cancer Awareness Month Draws Attention to Uneven Declines in Mortality

September 2nd 2025

ovarian cancer | Image Credit: MohammedElAmine - stock.adobe.com
Interval Cytoreductive Surgery Following Neoadjuvant Chemotherapy Improves Advanced Ovarian Cancer Outcomes

August 29th 2025

Advancing Ovarian Cancer Treatment: Insights From Emerging Therapies

Discover how advancements in BRCA, folate receptor alpha, HER2, and CCNE1 testing are shaping ovarian cancer care while addressing barriers in education, access, and tumor diversity.

AJMC Insights logo displayed over a dark blue abstract background with flowing wave-like patterns.
Continuing Medical Education
View All
September 18th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 18th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

dr diane mahoney
July 25th 2024

Dr Diane Mahoney on Tackling Ovarian Cancer Care Disparities

Brooke McCormick
In part 2 of our interview, Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, advocates for a multidisciplinary, community-centered approach to reduce ovarian cancer care disparities and stresses the need for ongoing exploration of social, biological, and environmental factors affecting health outcomes.
dr diane mahoney
July 23rd 2024

Dr Diane Mahoney Uncovers Health Disparities Among Black, Hispanic Ovarian Cancer Survivors

Brooke McCormick
Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, discusses her study on how social determinants of health impact the health perceptions of Black and Hispanic ovarian cancer survivors, highlighting significant health disparities.
what we're reading logo
July 18th 2024

What We’re Reading: Misleading ACA Ads; Codifying Roe v Wade; Ovarian Cancer Risk in Women With Endometriosis

AJMC Staff
Misleading ads are under scrutiny for their role in signing up consumers for Affordable Care Act (ACA) coverage without their permission; Sen Elizabeth Warren (D, Massachusetts) said there are enough votes in the Senate to suspend the filibuster to codify Roe v Wade in 2025 with a Democratic majority; women with endometriosis have about a fourfold risk of developing ovarian cancer.
Black female patient | Image Credit: Seventyfour - stock.adobe.com
July 17th 2024

SDOH Factors Impact Health Perceptions in Black, Hispanic Ovarian Cancer Survivors

Brooke McCormick
Social determinants of health (SDOH) factors significantly impact the overall health perceptions of Black and Hispanic ovarian cancer survivors.
Patient holding metformin prescription | Image Credit: Sherry Young - stock.adobe.com
July 9th 2024

Metformin Use Linked to Better Survival Rates in Patients With Ovarian Cancer

Brooke McCormick
Metformin use is linked to improved survival rates in patients with ovarian cancer, particularly among those with diabetes and serous cancers, though further research is needed to confirm these findings.
Drawing of a diverse group of people | Image Credit: Stafeeva - stock.adobe.com
July 2nd 2024

Minority Patients With Gynecologic Cancers More Likely to Receive Treatment at Academic Facilities

Brooke McCormick
Minority patients with gynecologic cancers are more likely than White patients to receive treatment at academic facilities, a recent study found.
3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
June 30th 2024

Fertility-Sparing Surgery Outcomes Comparable With Radical Surgery in Stage I Epithelial Ovarian Cancer

Brooke McCormick
Researchers found no significant differences in disease-free survival, overall survival, and recurrence rates between fertility-sparing surgery and radical surgery for patients with stage I epithelial ovarian cancer.
Doctor holding animated uterus and ovaries anatomy | Image Credit: Orawan - stock.adobe.com
June 28th 2024

Study: NLR, PLR May Be Early Prognostic Markers for Patients With Ovarian Cancer

Brooke McCormick
High neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are associated with worse progression-free survival and 5-year overall survival in patients with ovarian cancer.
Ovarian cancer | Image credit: Lars Neumann - stock.adobe.com
June 26th 2024

Fears, Concerns for Patients and Loved Ones Intensify Due to Recurrent Ovarian Cancer

Julia Bonavitacola
Supportive care interventions could help address concerns and help patients during the recurrence of ovarian cancer.
Medical team in operating room | Image Credit: Georgii - stock.adobe.com
June 25th 2024

Study Highlights Differences in Cytoreduction's Impact on Survival Among Ovarian Cancer Subtypes

Brooke McCormick
The association between residual tumor volume after primary cytoreduction and survival was less consistent in patients with low-grade serous ovarian carcinoma (LGSOC) compared with other histology types, highlighting variability in surgical outcomes across ovarian cancer subtypes.
"Prognosis" written on blackboard | Image Credit: Yury Zap - stock.adobe.com
June 20th 2024

Surgery Plus Chemotherapy Shows Promise for Stage IV Epithelial Ovarian Cancer

Brooke McCormick
Patients with stage IV epithelial ovarian cancer (OC) treated with surgery and chemotherapy exhibit the best prognosis.
Female patient checking thyroid gland | Image Credit: Jo Panuwat D - stock.adobe.com
June 10th 2024

Hyperthyroidism Potentially Linked to Increased Ovarian Cancer Risk

Brooke McCormick
There may be a causal relaPatients with hyperthyroidism are at increased risk of ovarian cancer (OC), although the link between the conditions is not yet fully understood.
Salad, weights, and measuring tape | Image Credit: freebird7977 - stock.adobe.com
May 28th 2024

Exercise, Diet Interventions Boost Fat-Free Mass, Reduce Fatigue in Patients With OC

Brooke McCormick
Exercise and dietary interventions reduced fatigue and improved both fat-free mass and physical functioning in patients with ovarian cancer (OC), but no significant differences in improvement were found between the intervention and control groups.
Animation of a liver with cancer cell growth | Image Credit: Rasi - stock.adobe.com
May 21st 2024

Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases

Brooke McCormick
Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
What We’re Reading: Genetic Markers Predict Weight Loss Response; Talc Baby Powder Linked to Ovarian Cancer; Safeguard for IVF Access Nationwide
May 20th 2024

What We’re Reading: Predicting Weight Loss Response; Talc Baby Powder and Ovarian Cancer; Safeguarding IVF Access

AJMC Staff
Certain genes have been linked to significant weight reduction in obesity treatment; research boosts plaintiffs’ cases against Johnson & Johnson for their talc-based baby powder; proposed legislation aims to address concerns following Alabama Supreme Court ruling on embryos.
Female patient with hands over heart | Image Credit: fizkes - stock.adobe.com
May 17th 2024

Age, Tumor Metastasis, Surgical Treatment Contribute to Cardiovascular Mortality in Patients With Ovarian Cancer

Brooke McCormick
The researchers identified age, tumor metastasis, and surgical treatment as key independent prognostic factors for cardiovascular mortality in patients with ovarian cancer, highlighting the need for individualized treatment and surveillance strategies.
Patient with red eye | Image Credit: Kryuchka Yaroslav - stock.adobe.com
May 13th 2024

Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence

Brooke McCormick
Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Ovarian cancer | Image credit: blueringmedia - stock.adobe.com
May 1st 2024

BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer

Rose McNulty
Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
3D illustration of ovarian cancer | Image Credit: Lars Neumann - stock.adobe.com
April 24th 2024

Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases

Brooke McCormick
This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Patient in hospital bed | Image Credit: Gorodenkoff - stock.adobe.com
April 21st 2024

Black Patients With Ovarian Cancer Had Lower-Quality End-of-Life Care, Study Says

Brooke McCormick
Non-Hispanic Black (NHB) patients with ovarian cancer (OC) receive lower-quality end of life (EOL) care compared to their non-Hispanic White (NHW) counterparts, according to a study.
Chemotherapy | Image Credit: tashatuvango - stock.adobe.com
April 17th 2024

Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US

Brooke McCormick
There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Ovarian cancer illustration | Image credit: Chrystal light - stock.adobe.com
April 12th 2024

Most Patients With Mucinous Ovarian Cancer Don't Need Perioperative GI Endoscopy

Rose McNulty
A new study suggests routine gastrointestinal (GI) endoscopy is not needed for most patients with mucinous ovarian cancer in the perioperative setting due to a lack of statistically significant overall survival benefits.
Ovarian cancer | Image credit: blueringmedia - stock.adobe.com
April 4th 2024

Model Including Diffusion-Weighted MRI More Accurately Predicts Ovarian Cancer Resectability

Rose McNulty
A recent study suggests a modified model incorporating diffusion-weighted MRI can more accurately predict ovarian cancer primary debulking surgery outcomes compared with the standard, widely used Memorial Sloan Kettering Cancer Center risk model.
Patients Treated With Mirvetuximab Soravtansine vs Chemotherapy Report Better HRQOL
March 29th 2024

Patients Treated With Mirvetuximab Soravtansine vs Chemotherapy Report Better HRQOL

Rose McNulty
An abstract presented at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer explored patient-reported health-related quality of life (HRQOL) among patients treated with mirvetuximab soravtansine compared with standard chemotherapy.
FDA approved - Image credit: wladimir1804 - stock.adobe.com
March 22nd 2024

Mirvetuximab Soravtansine-gynx Granted Full FDA Approval for FRα+ Platinum-Resistant Ovarian Cancer

Rose McNulty
Mirvetuximab soravtansine-gynx (Elahere) received full FDA approval for the treatment of folate receptor alpha–positive (FRα+), platinum-resistant ovarian cancer (PROC) based on findings from the confirmatory phase 3 MIRASOL trial.
Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"
March 18th 2024

Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.
Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"
March 18th 2024

Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

A medical professional examines the pivotal roles of molecular profiling, next-generation sequencing, and germline testing in guiding treatment decisions for ovarian cancer.
Colored Genetic Code DNA Molecule Structure | Image credit: ktsdesign - stock.adobe.com
March 15th 2024

Study Identifies Potential Genomic Markers for Residual Ovarian Cancer Following Resection

Rose McNulty
A recent study found that certain gene variants may be prognostic for residual disease following resection in patients with ovarian cancer.
AI image of microscope looking at ovarian cancer cells | Image credit: Justlight - stock.adobe.com
March 6th 2024

Tumor-Stroma Proportion Predicts Clinical Outcomes in Ovarian Cancer

Rose McNulty
A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.
Ovarian cancer | Image credit: Crystal light - stock.adobe.com
March 1st 2024

CA-125 Shows Poor Concordance With Radiologic Progression in Ovarian Cancer

Rose McNulty
Current treatment guidelines recommend using cancer antigen-125 (CA-125) as a diagnostic marker for ovarian cancer recurrence, but a recent study suggests CA-125 has poor concordance with progressive disease based on RECIST criteria.
<12345678>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo